
GE HealthCare Technologies Inc.: shareholders and insiders
Price
$80.64
November 20, 2026Market cap $36.8B
What Ploutos Investor adds for GE HealthCare Technologies
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
$6.4M
8 people
Sold on the market
–
nobody
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $6.4M by 8 people·no sales
- 2025: no buys, no sales
- 2026: bought $6.4M by 8 people, no sales
- Nov 16, 2026Neal Joseph SandyCEO, Patient Care SolutionsKind
- Sep 14, 2026William K GroganChief Financial OfficerKind
- Sep 14, 2026William K GroganChief Financial OfficerKind
- Sep 3, 2026Philip RackliffeCEO, AISKind
- Sep 3, 2026Kevin Michael O'NeillCEO, PDxKind
- Sep 3, 2026George A. NewcombChief Accounting OfficerKind
- Sep 3, 2026Taha Kass-HoutChief Technology OfficerKind
- Sep 3, 2026Frank R JimenezGC & Corporate SecretaryKind
- Sep 3, 2026Adam Y HoltonChief People OfficerKind
- Sep 3, 2026Catherine EstrampesChief Commer. & Growth OfficerKind
- Sep 3, 2026Peter J ArduiniPresident and CEOKind
- Sep 1, 2026Philip RackliffeCEO, AISKind
- Sep 1, 2026Philip RackliffeCEO, AISKind
- Sep 1, 2026Philip RackliffeCEO, AISKind
- Sep 1, 2026Taha Kass-HoutChief Technology OfficerKind
- Sep 1, 2026Taha Kass-HoutChief Technology OfficerKind
- Sep 1, 2026Frank R JimenezGC & Corporate SecretaryKind
- Sep 1, 2026Frank R JimenezGC & Corporate SecretaryKind
- Sep 1, 2026Adam Y HoltonChief People OfficerKind
- Sep 1, 2026Jeannette BankesCEO, Patient Care SolutionsKind
- Sep 1, 2026Peter J ArduiniPresident and CEOKind
- Sep 1, 2026Peter J ArduiniPresident and CEOKind
- Aug 15, 2026Adam Y HoltonChief People OfficerKind
- May 22, 2026Kevin LoboDirectorKind
- May 12, 2026Rodney F HochmanKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Neal Joseph SandyCEO, Patient Care Solutions | 1,018 | – | – | Form 4 | |
| Sep 14, 2026 | William K GroganChief Financial Officer | 62.3K | – | – | Form 4 | |
| Sep 14, 2026 | William K GroganChief Financial Officer | 12.8K | – | – | Form 4 | |
| Sep 3, 2026 | Philip RackliffeCEO, AIS | 798 | $70.56 | $56.3K | Form 4 | |
| Sep 3, 2026 | Kevin Michael O'NeillCEO, PDx | 718 | $70.56 | $50.7K | Form 4 | |
| Sep 3, 2026 | George A. NewcombChief Accounting Officer | 112 | $70.56 | $7.9K | Form 4 | |
| Sep 3, 2026 | Taha Kass-HoutChief Technology Officer | 1,502 | $70.56 | $106.0K | Form 4 | |
| Sep 3, 2026 | Frank R JimenezGC & Corporate Secretary | 1,480 | $70.56 | $104.4K | Form 4 | |
| Sep 3, 2026 | Adam Y HoltonChief People Officer | 673 | $70.56 | $47.5K | Form 4 | |
| Sep 3, 2026 | Catherine EstrampesChief Commer. & Growth Officer | 508 | $70.56 | $35.8K | Form 4 | |
| Sep 3, 2026 | Peter J ArduiniPresident and CEO | 6,303 | $70.56 | $444.7K | Form 4 | |
| Sep 1, 2026 | Philip RackliffeCEO, AIS | 290 | $71.23 | $20.7K | Form 4 | |
| Sep 1, 2026 | Philip RackliffeCEO, AIS | 226 | $71.23 | $16.1K | Form 4 | |
| Sep 1, 2026 | Philip RackliffeCEO, AIS | 340 | $71.23 | $24.2K | Form 4 | |
| Sep 1, 2026 | Taha Kass-HoutChief Technology Officer | 1,644 | $71.23 | $117.1K | Form 4 | |
| Sep 1, 2026 | Taha Kass-HoutChief Technology Officer | 1,296 | $71.23 | $92.3K | Form 4 | |
| Sep 1, 2026 | Frank R JimenezGC & Corporate Secretary | 1,751 | $71.23 | $124.7K | Form 4 | |
| Sep 1, 2026 | Frank R JimenezGC & Corporate Secretary | 1,380 | $71.23 | $98.3K | Form 4 | |
| Sep 1, 2026 | Adam Y HoltonChief People Officer | 659 | $71.23 | $46.9K | Form 4 | |
| Sep 1, 2026 | Jeannette BankesCEO, Patient Care Solutions | 1,064 | $71.23 | $75.8K | Form 4 | |
| Sep 1, 2026 | Peter J ArduiniPresident and CEO | 6,043 | $71.23 | $430.4K | Form 4 | |
| Sep 1, 2026 | Peter J ArduiniPresident and CEO | 5,472 | $71.23 | $389.8K | Form 4 | |
| Aug 15, 2026 | Adam Y HoltonChief People Officer | 1,360 | $73.69 | $100.2K | Form 4 | |
| May 22, 2026 | Kevin LoboDirector | 10.0K | $64.18 | $641.8K | Form 4 | |
| May 12, 2026 | Rodney F Hochman | 1,618 | $62.03 | $100.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 26, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by GEHC's officers and directors from 2023 up to November 19, 2025, 3 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Trian Fund Mgmt (Peltz)In the quarter
- Point72 (Cohen)In the quarter-51%
- Citadel Advisors (Griffin)In the quarter-26%
- Millennium Mgmt (Englander)In the quarter+175%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter+68%
- Bridgewater (Dalio)In the quarter-5.0%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Trian Fund Mgmt (Peltz) | 3.09M | $202M | 7.77% | |
| Point72 (Cohen) | 568.7K | -51% | $37M | 0.06% |
| Citadel Advisors (Griffin) | 1.74M | -26% | $114M | 0.06% |
| Millennium Mgmt (Englander) | 796.9K | +175% | $52M | 0.04% |
| D.E. Shaw | – | – | 0.02% | |
| AQR Capital | 1.17M | +68% | $77M | 0.02% |
| Bridgewater (Dalio) | 14.8K | -5.0% | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 4.25% of its shares outstanding were held short, +4.6% since the report before.
- Shares held short
- 19.37M
- 4.25%
- Since the report before18.52M on Sep 30, 2026
- +4.6%
- 5.1
- 3.78M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 62%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 14.44M
- Nov 15, 2023: Shares held short 16.55M
- Nov 30, 2023: Shares held short 16.61M
- Dec 15, 2023: Shares held short 15.62M
- Dec 29, 2023: Shares held short 15.52M
- Jan 12, 2024: Shares held short 14.68M
- Jan 31, 2024: Shares held short 15.66M
- Feb 15, 2024: Shares held short 15.06M
- Feb 29, 2024: Shares held short 13.21M
- Mar 15, 2024: Shares held short 12.29M
- Mar 28, 2024: Shares held short 12.17M
- Apr 15, 2024: Shares held short 10.95M
- Apr 30, 2024: Shares held short 11.58M
- May 15, 2024: Shares held short 10.36M
- May 31, 2024: Shares held short 11.64M
- Jun 14, 2024: Shares held short 11.93M
- Jun 28, 2024: Shares held short 12.31M
- Jul 15, 2024: Shares held short 12.71M
- Jul 31, 2024: Shares held short 11.86M
- Aug 15, 2024: Shares held short 10.50M
- Aug 30, 2024: Shares held short 10.01M
- Sep 13, 2024: Shares held short 10.10M
- Sep 30, 2024: Shares held short 11.54M
- Oct 15, 2024: Shares held short 9.12M
- Oct 31, 2024: Shares held short 8.28M
- Nov 15, 2024: Shares held short 8.72M
- Nov 29, 2024: Shares held short 8.67M
- Dec 13, 2024: Shares held short 9.24M
- Dec 31, 2024: Shares held short 12.15M
- Jan 15, 2025: Shares held short 12.76M
- Jan 31, 2025: Shares held short 9.69M
- Feb 14, 2025: Shares held short 9.24M
- Feb 28, 2025: Shares held short 10.07M
- Mar 14, 2025: Shares held short 9.81M
- Mar 31, 2025: Shares held short 8.22M
- Apr 15, 2025: Shares held short 8.22M
- Apr 30, 2025: Shares held short 6.66M
- May 15, 2025: Shares held short 6.81M
- May 30, 2025: Shares held short 6.17M
- Jun 13, 2025: Shares held short 6.39M
- Jun 30, 2025: Shares held short 7.88M
- Jul 15, 2025: Shares held short 6.62M
- Jul 31, 2025: Shares held short 9.02M
- Aug 15, 2025: Shares held short 8.40M
- Aug 29, 2025: Shares held short 7.36M
- Sep 15, 2025: Shares held short 7.46M
- Sep 30, 2025: Shares held short 7.94M
- Oct 15, 2025: Shares held short 7.92M
- Oct 31, 2025: Shares held short 11.24M
- Nov 14, 2025: Shares held short 9.27M
- Nov 28, 2025: Shares held short 11.14M
- Dec 15, 2025: Shares held short 11.77M
- Dec 31, 2025: Shares held short 11.20M
- Jan 15, 2026: Shares held short 10.80M
- Jan 30, 2026: Shares held short 9.97M
- Feb 13, 2026: Shares held short 10.01M
- Feb 27, 2026: Shares held short 10.88M
- Mar 13, 2026: Shares held short 11.03M
- Mar 31, 2026: Shares held short 12.36M
- Apr 15, 2026: Shares held short 12.14M
- Apr 30, 2026: Shares held short 12.06M
- May 15, 2026: Shares held short 12.18M
- May 29, 2026: Shares held short 14.67M
- Jun 15, 2026: Shares held short 15.58M
- Jun 30, 2026: Shares held short 14.37M
- Jul 15, 2026: Shares held short 18.45M
- Jul 31, 2026: Shares held short 19.39M
- Aug 14, 2026: Shares held short 17.43M
- Aug 31, 2026: Shares held short 18.96M
- Sep 15, 2026: Shares held short 16.91M
- Sep 30, 2026: Shares held short 18.52M
- Oct 15, 2026: Shares held short 19.37M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading48.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 48.0% of the shares in the reported trades were short sales, against 53.4% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 48.0%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 53.4%
- Change
- -5.4 pts
- Short sales a dayon average, of 1.64M shares
- 786.6K
- More than atof 3,666 US-listed companies, same days
- 41%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 72.5%
- Oct 14, 2026: Short sales 70.6%
- Oct 15, 2026: Short sales 56.3%
- Oct 16, 2026: Short sales 55.6%
- Oct 19, 2026: Short sales 42%
- Oct 20, 2026: Short sales 59.8%
- Oct 21, 2026: Short sales 64.6%
- Oct 22, 2026: Short sales 58.5%
- Oct 23, 2026: Short sales 56.8%
- Oct 26, 2026: Short sales 48.3%
- Oct 27, 2026: Short sales 49.7%
- Oct 28, 2026: Short sales 41.6%
- Oct 29, 2026: Short sales 49.4%
- Oct 30, 2026: Short sales 52.1%
- Nov 2, 2026: Short sales 39.3%
- Nov 3, 2026: Short sales 24.7%
- Nov 4, 2026: Short sales 41%
- Nov 5, 2026: Short sales 52.7%
- Nov 6, 2026: Short sales 54.9%
- Nov 9, 2026: Short sales 44.1%
- Nov 10, 2026: Short sales 56.3%
- Nov 11, 2026: Short sales 49.1%
- Nov 12, 2026: Short sales 58.7%
- Nov 13, 2026: Short sales 70.7%
- Nov 16, 2026: Short sales 66.9%
- Nov 17, 2026: Short sales 54.1%
- Nov 18, 2026: Short sales 55.1%
- Nov 19, 2026: Short sales 57.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Peter J ArduiniPresident and CEODirectly241.6K
- H Lawrence Culp JrDirectorDirectly–
- Frank R JimenezGC & Corporate SecretaryDirectly89.3K
- Taha Kass-HoutChief Technology OfficerDirectly88.5K
- James SaccaroChief Financial OfficerDirectly87.5K
- William K GroganChief Financial OfficerDirectly75.1K
- Jan MakelaCEO, ImagingDirectly63.3K
- Philip RackliffeCEO, AVSDirectly41.5K
- Kenneth R. StacherskiCh. Supply Chain & Serv. Ofc.Directly38.5K
- Jeannette BankesCEO, Patient Care SolutionsDirectly37.3K
- Kevin Michael O'NeillCEO, PDxDirectly32.1K
- Roland RottCEO, ImagingDirectly24.3K
- Catherine EstrampesChief Commer. & Growth OfficerDirectly23.6K
- Adam Y HoltonChief People OfficerDirectly19.5K
- Thomas J. WestrickCEO, Patient Care SolutionsDirectly17.5K
- William J StrombergDirectorDirectly15.3K
- Kevin LoboDirectorDirectly14.4K
- Watkin Phoebe L. YangDirectorDirectly13.7K
- George A. NewcombChief Accounting OfficerDirectly10.5K
- Neal Joseph SandyCEO, Patient Care SolutionsDirectly4,798
- Rodney F HochmanDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Peter J ArduiniPresident and CEO | 241.6K | – | Sep 3, 2026 | Form 4 |
| H Lawrence Culp JrDirector | – | 151.2K | May 6, 2026 | Form 4 |
| Frank R JimenezGC & Corporate Secretary | 89.3K | – | Sep 3, 2026 | Form 4 |
| Taha Kass-HoutChief Technology Officer | 88.5K | – | Sep 3, 2026 | Form 4 |
| James SaccaroChief Financial Officer | 87.5K | – | May 1, 2026 | Form 4 |
| William K GroganChief Financial Officer | 75.1K | – | Sep 14, 2026 | Form 4 |
| Jan MakelaCEO, Imaging | 63.3K | – | May 15, 2024 | Form 4 |
| Philip RackliffeCEO, AVS | 41.5K | – | Sep 3, 2026 | Form 4 |
| Kenneth R. StacherskiCh. Supply Chain & Serv. Ofc. | 38.5K | – | Aug 14, 2024 | Form 4 |
| Jeannette BankesCEO, Patient Care Solutions | 37.3K | – | Sep 1, 2026 | Form 4 |
| Kevin Michael O'NeillCEO, PDx | 32.1K | – | Sep 3, 2026 | Form 4 |
| Roland RottCEO, Imaging | 24.3K | – | Nov 6, 2024 | Form 4 |
| Catherine EstrampesChief Commer. & Growth Officer | 23.6K | – | Sep 3, 2026 | Form 4 |
| Adam Y HoltonChief People Officer | 19.5K | – | Sep 3, 2026 | Form 4 |
| Thomas J. WestrickCEO, Patient Care Solutions | 17.5K | – | Aug 7, 2024 | Form 4 |
| William J StrombergDirector | 15.3K | – | May 6, 2026 | Form 4 |
| Kevin LoboDirector | 14.4K | – | May 22, 2026 | Form 4 |
| Watkin Phoebe L. YangDirector | 13.7K | – | May 8, 2026 | Form 4 |
| George A. NewcombChief Accounting Officer | 10.5K | – | Sep 3, 2026 | Form 4 |
| Neal Joseph SandyCEO, Patient Care Solutions | 4,798 | – | Nov 16, 2026 | Form 4 |
| Rodney F HochmanDirector | – | 1,618 | May 12, 2026 | Form 4 |
A lower bound: it counts only the 21 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$19M
Actually paid: $20M
$5.7M
Actually paid: $5.7M
$136
Peers: $122
Organic revenue growth*
From the proxy statement (DEF 14A) of Mar 19, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount$200M
- Mar 31, 202610-QAmount$100M
- Sep 30, 202510-QAmount$100M
- Jun 30, 202510-QAmount$100M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | 3.28M | $61.05 | $200M | $500M | 10-Q |
| Mar 31, 202610-Q | 1.40M | $71.35 | $100M | $700M | 10-Q |
| Sep 30, 202510-Q | 1.39M | $71.98 | $100M | $800M | 10-Q |
| Jun 30, 202510-Q | 1.43M | $70.06 | $100M | $900M | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 11, 2026For96.4%
- 2025May 30, 2025For94.7%
- 2024May 23, 2024For93.1%
- 2023May 25, 2023For97.1%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 11, 2026 | 96.4% | 351M | 12.97M | 795.2K | 34.60M | 8-K |
| 2025May 30, 2025 | 94.7% | 338M | 18.94M | 1.13M | 39.55M | 8-K |
| 2024May 23, 2024 | 93.1% | 333M | 24.51M | 2.00M | 41.72M | 8-K |
| 2023May 25, 2023 | 97.1% | 347M | 10.53M | 1.38M | 39.24M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund4.51%
- MOATVanEck Morningstar Wide Moat ETFWeight in the fund2.21%
- JAVAJPMorgan Active Value ETFWeight in the fund1.08%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.51%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund0.51%
- VOEVanguard Mid-Cap Value Index FundWeight in the fund0.50%
- VHTVanguard Health Care Index FundWeight in the fund0.45%
- IXJiShares Global Healthcare ETFWeight in the fund0.38%
- AIQGlobal X Artificial Intelligence & Technology ETFWeight in the fund0.31%
- IWSiShares Russell Mid-Cap Value ETFWeight in the fund0.29%
53 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 1,280
- Q4 2025: Managers 1,339
- Q1 2026: Managers 1,278
- Q2 2026: Managers 1,226
Institutional investors by quarter
The fund managers holding GEHC, quarter by quarter, from Q2 2022 to Q2 2025, 12 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 1,226 managers held 394M shares, worth $25.2B. During the quarter 135 opened a position, 187 closed one, 388 added and 467 trimmed.
The largest holders, Q2 2026
- Dodge & CoxIn the quarter+21%
- BlackRockIn the quarter+4.1%
- Vanguard Capital ManagementIn the quarter+3.0%
- State StreetIn the quarter+1.6%
- Vanguard Portfolio ManagementIn the quarter+5.7%
- InvescoIn the quarter+5.7%
- Harris Associates L PIn the quarter-1.7%
- Barrow Hanley Mewhinney & StraussIn the quarter+13%
- Geode Capital ManagementIn the quarter+3.8%
- Hotchkis & Wiley Capital ManagementIn the quarter+23%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Dodge & Cox | 37.86M | +21% | $2.4B |
| BlackRock | 37.47M | +4.1% | $2.4B |
| Vanguard Capital Management | 29.72M | +3.0% | $1.9B |
| State Street | 20.86M | +1.6% | $1.3B |
| Vanguard Portfolio Management | 20.28M | +5.7% | $1.3B |
| Invesco | 18.30M | +5.7% | $1.2B |
| Harris Associates L P | 15.33M | -1.7% | $981M |
| Barrow Hanley Mewhinney & Strauss | 13.46M | +13% | $861M |
| Geode Capital Management | 12.87M | +3.8% | $821M |
| Hotchkis & Wiley Capital Management | 12.25M | +23% | $784M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do GE HealthCare Technologies's filings show?
Who buys and sells is one part of GE HealthCare Technologies's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GEHC's insiders bought or sold?
From May 26, 2026 to Nov 18, 2026 GE HealthCare Technologies's insiders bought $641.8K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold GEHC?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was Trian Fund Mgmt (Peltz)'s, worth $202M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.